More on CYTR

- Summary
- Chart
- Profile
- Historical


- Earnings (-28.6% Growth)
- Ratings (8.3 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (11/3/16 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 58.88M
Marketable securities 0
Proceeds from sale of RXi, received January 6, 2011
Receivable 108.35K
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable
Prepaid expenses and other current assets 2.62M
Total current assets 61.6M
Equipment and furnishings, net 2.07M
Goodwill 183.78K
Other assets 54.65K
Total assets 63.91M
Current liabilities:
Accounts payable 4.82M
Accrued expenses and other current liabilities 5.05M
Warrant liabilities 6.69M
Total current liabilities 20.11M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 96.94K
Additional paid-in capital 431.69M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares)
Accumulated deficit -408.19M
Total stockholders' equity 23.6M
Total liabilities and stockholders' equity 63.91M